Can You Rebuild Cartilage in Your Hip?

Hip cartilage has almost no ability to rebuild itself once damaged, because it lacks the blood supply that most tissues rely on for healing. That biological reality shapes everything about treatment: the approaches that exist are attempts to work around a fundamental limitation, not to flip a regenerative switch the body already has. Some surgical and biological therapies can partially restore cartilage or generate replacement tissue, but the results depend heavily on the size and location of the damage, your age, and how far the joint has deteriorated. The honest picture is more nuanced than either “cartilage is gone forever” or “stem cells will fix it.”

Why Hip Cartilage Does Not Heal on Its Own

Articular cartilage, the smooth, rubbery layer that coats the ends of bones inside a joint, is unlike most tissues in the body. It has no blood vessels, no lymphatic drainage, and no nerves running through it. When you cut your skin, blood rushes to the wound site, delivers immune cells, and forms a clot that becomes the scaffold for new tissue. Cartilage cannot do any of that. Damage that stays within the cartilage layer does not trigger the normal inflammatory repair cascade, so the tissue tends to degrade further rather than mend itself.¹

The hip adds its own complications. It is a deep, ball-and-socket joint that bears tremendous load with every step. Conditions like femoroacetabular impingement, where the ball and socket don’t fit together smoothly, can grind away cartilage during routine movements like bending and rotating the leg.² By the time hip cartilage loss causes pain, the damage is often well established. This is why so many people with hip osteoarthritis eventually face joint replacement: the cartilage never had a real shot at recovering.

The Replacement Tissue Problem

Even when a treatment does stimulate new tissue growth in a joint, the tissue that forms is usually not the same stuff that was there originally. Healthy joint cartilage is called hyaline cartilage, and it has a specific architecture of collagen fibers and water-binding molecules that lets it absorb shock and glide smoothly. When the body is prompted to fill in a cartilage defect, what it typically produces is fibrocartilage, a rougher, stiffer tissue built with different collagen. Fibrocartilage has weaker mechanical properties and tends to break down faster, which can lead to further joint deterioration over time.³⁴

This distinction matters because it sets the bar for every cartilage repair strategy. The question is not just whether new tissue fills the gap, but whether that tissue is durable enough to hold up under the forces the hip experiences daily. Many treatments that look promising on an MRI at six months start showing wear at three to five years, especially in large defects or in patients who put heavy demands on the joint.⁵

Microfracture Surgery

Microfracture is one of the most established surgical techniques for cartilage repair, and it works by deliberately piercing tiny holes into the bone beneath a cartilage defect. The idea is to let blood and marrow cells seep up from the bone into the damaged area, forming a clot that eventually matures into repair tissue. The surgery is relatively simple and can be done arthroscopically through small incisions.

In the hip, microfracture is most commonly performed during arthroscopy for femoroacetabular impingement when surgeons find areas of full-thickness cartilage loss on the acetabulum (the hip socket). A study following patients for at least ten years after hip arthroscopy with acetabular microfracture found that about 77% of patients had not needed a hip replacement by that point, and those who kept their native hip showed meaningful improvements in pain and function scores.⁶ That is encouraging, but it also means roughly one in four patients eventually needed a total hip replacement. And the tissue that microfracture produces is predominantly fibrocartilage, not the original hyaline type, which raises durability questions over longer time horizons.

Growing Your Own Cartilage Cells Back In

A more sophisticated approach involves harvesting a small sample of your own healthy cartilage cells, growing them in a lab, and then implanting them back into the defect. This is called autologous chondrocyte implantation (ACI), and a newer version called matrix-induced autologous chondrocyte implantation (MACI) seeds the cells onto a collagen membrane before implantation. The membrane gives the cells a structure to grow on and makes it easier for the surgeon to place them precisely.

In the hip, MACI is a two-stage procedure. During the first arthroscopy, the surgeon takes cartilage fragments from a non-weight-bearing area near the joint. Those cells go to a lab for several weeks of culturing. In a second surgery, the surgeon cleans out the damaged area, inserts the cell-seeded membrane through an arthroscopic cannula, and positions it over the defect. The concave shape of the hip socket and the pressure from the femoral head help hold the implant in place once traction is released.⁷

Clinical results from a series of 29 patients who had ACI in the hip showed significant improvement in pain and function scores at two years compared to baseline. Quality-of-life scores jumped from an average of about 49 before surgery to roughly 67 at two years, and hip function scores rose from about 67 to 80 over the same period.⁸ These are small case series, not large randomized trials, so the evidence is still early-stage. The procedure also has strict selection criteria: it is generally limited to patients under fifty with full-thickness defects of at least two square centimeters, in joints that still have adequate overall joint space.⁷ If osteoarthritis has already narrowed the joint significantly, the procedure is not an option.

Stem Cell Injections

Stem cell therapy for cartilage repair, particularly using mesenchymal stem cells (MSCs) harvested from bone marrow or fat tissue, has generated enormous public interest. The concept is appealing: inject cells that can transform into cartilage-building chondrocytes, release growth factors that tamp down inflammation, and potentially regenerate damaged tissue. Research reviews have found that injecting MSCs into arthritic joints does reduce pain, reduce inflammation, and show some evidence of cartilage regeneration on MRI.⁹

The catch is that the cartilage improvements seen on imaging tend to be partial. A review of clinical trials concluded that while MSC injections are helpful for osteoarthritis symptoms and do appear to promote some cartilage repair, they are likely insufficient for fully restoring articular cartilage defects.¹⁰ Much of the benefit may come from the anti-inflammatory and pain-relieving effects of the injected cells rather than true structural rebuilding. There is also wide variation in how clinics prepare and deliver stem cell treatments, which makes it hard to compare results across studies. If you are considering this route, it is worth knowing that the field is still working out optimal cell sources, doses, and delivery methods.

PRP and Hyaluronic Acid Injections

Platelet-rich plasma (PRP) is made by spinning a sample of your own blood to concentrate the platelets and their growth factors, then injecting that concentrate into the joint. In laboratory studies, PRP stimulates cartilage cells to multiply and produce more of the structural matrix that holds cartilage together, while also dampening inflammation.¹¹ Clinical experience suggests PRP can reduce hip pain for months after injection, though the evidence for actual cartilage regrowth in humans is less convincing than the lab data. PRP is better thought of as a way to improve the joint environment and slow degradation than as a cartilage-rebuilding treatment.

Hyaluronic acid (HA) injections, sometimes called viscosupplementation, work differently. HA is a natural component of joint fluid, and injecting it into the hip aims to improve lubrication and cushioning. In animal models of post-traumatic osteoarthritis, HA injections preserved more of the joint’s original collagen structure and slowed cartilage breakdown compared to untreated joints, with cross-linked formulations showing somewhat stronger and longer-lasting effects.¹² Whether these findings translate fully to human hips is still being studied, but HA injections are widely used in clinical practice for symptom relief.

Do Supplements Help?

Glucosamine and chondroitin sulfate are two of the most popular over-the-counter supplements marketed for joint health. Meta-analyses of their use in knee osteoarthritis have found a small but statistically significant slowing of joint space narrowing, which is an indirect marker of cartilage preservation.¹³ “Small but significant” is worth unpacking: the effect is real enough to detect across studies but modest enough that many individual users would not notice a dramatic difference. Most of this evidence comes from knee studies, and the hip may not respond identically.

Collagen supplements have also attracted attention. A systematic review found that every preclinical and clinical study examined reported some benefit from collagen derivatives for osteoarthritis and cartilage repair, whether the collagen was taken orally or injected into the joint.¹⁴ That sounds striking, but it is worth noting that industry-funded supplement studies tend to find positive results, and the range of doses, formulations, and outcomes measured across trials was wide. These supplements are unlikely to rebuild lost cartilage outright, but they may contribute to slowing further loss, especially when combined with other interventions.

Exercise, Weight, and Mechanical Loading

Cartilage is not an inert cap sitting on the end of a bone. It is a living tissue that absorbs and releases water as you load and unload it, and this cycling of compression and recovery is essential for bringing nutrients into the tissue and flushing waste out. Studies measuring cartilage volume before and after exercise have shown that activities like knee bends compress cartilage by around five to six percent, and it takes roughly ninety minutes of rest to fully recover that volume.¹⁵ This compress-and-recover cycle is thought to be how cartilage maintains itself, which is one reason why moderate, regular exercise is recommended for people with osteoarthritis even though it might seem counterintuitive to load an already-damaged joint.

Weight loss is often recommended for hip osteoarthritis on the assumption that reducing mechanical load will protect remaining cartilage. But the relationship between weight change and hip joint outcomes is not as straightforward as you might expect. A study tracking structural and pain outcomes over four years found no significant associations between weight change and hip imaging measurements or hip pain.¹⁶ This does not mean weight does not matter for hip health, since the hip’s biomechanics differ from the knee’s and other studies have found general health benefits from weight management. But it does suggest that weight loss alone is unlikely to measurably reverse or halt hip cartilage loss the way people sometimes hope.

Experimental Growth Factors and Drug Therapies

One of the most closely watched developments in cartilage science is the search for a disease-modifying osteoarthritis drug, something that could actually slow or reverse cartilage loss rather than just manage symptoms. Sprifermin, a lab-made version of fibroblast growth factor 18, is the most advanced candidate. In preclinical studies, sprifermin consistently improved cartilage defect repair and promoted formation of tissue that looked and stained like mature hyaline cartilage rather than the typical fibrocartilage.¹⁷

Human trials have confirmed that sprifermin injections produce a measurable and lasting increase in cartilage thickness and volume. However, in the overall study populations, these structural gains did not translate into significant symptom improvement compared to placebo. A subgroup of patients with more advanced disease did show meaningful pain reduction, hinting that structural benefits might matter most when the joint is already substantially degraded.¹⁸ Laboratory work has shown that sprifermin’s effect on cartilage matrix follows a two-phase pattern: it initially breaks down and remodels existing tissue before ramping up new collagen production in a later phase.¹⁹ Sprifermin is not yet approved as a treatment, but it represents the closest anyone has come to a drug that genuinely rebuilds cartilage.

Tissue Engineering and 3D Bioprinting

The most futuristic cartilage repair strategies involve building replacement tissue from scratch outside the body. Researchers are developing scaffolds, three-dimensional structures made from biocompatible materials, that serve as a framework for cartilage cells to grow on. Some of the most promising scaffolds combine gelatin-based hydrogels with other materials to create structures that mimic the mechanical properties of natural cartilage while keeping seeded cells alive and productive.

Recent work has produced scaffolds with dramatically improved strength. One approach using a silk-fibroin-reinforced hydrogel achieved compression resistance about five times greater than the hydrogel alone while maintaining over 90% cell survival, and when implanted in animal models, the scaffolds produced tissue rich in the collagen type that characterizes healthy hyaline cartilage.²⁰ Other groups have developed multi-layered constructs using stem cells from fat tissue in combination with bioprinted hydrogel scaffolds, producing structures that show both cartilage formation and vascular integration in larger grafts.²¹

This technology is still in laboratory and early animal-testing stages. The leap from a small construct grown under a mouse’s skin to a functional cartilage surface inside a weight-bearing human hip joint is enormous. But the field is progressing rapidly, and bioprinted cartilage grafts may eventually offer a way to patch larger defects with tissue that behaves more like the real thing than anything current surgeries can produce.

Gene Therapy for Cartilage

Gene therapy takes a different angle entirely. Instead of adding cells or scaffolds, the idea is to deliver genetic instructions into the joint that cause the tissue’s own cells to produce therapeutic proteins on an ongoing basis. One approach that has reached clinical testing involves injecting a mixture of normal cartilage cells and cells that have been genetically modified to produce TGF-β1, a growth factor involved in cartilage maintenance. This product, known as TissueGene-C, has been tested in patients with knee osteoarthritis.²²

Adeno-associated virus (AAV) vectors are particularly interesting for joint cartilage because they can penetrate deep into cartilage tissue and deliver genes directly to chondrocytes in place, something most other viral delivery systems cannot do.²² In theory, a single injection could turn the joint’s resident cells into ongoing producers of repair-promoting molecules. The practical challenges are substantial, including controlling how much protein the cells produce, making sure the effect does not spread beyond the joint, and ensuring long-term safety. Gene therapy for cartilage remains years from routine clinical use, but it represents one of the few approaches that could, in principle, create a self-sustaining repair response in tissue that normally refuses to heal.

When Repair Is Not Realistic

All of the cartilage-preserving and cartilage-repairing strategies described above work best when damage is caught early, when defects are focal and contained, and when the overall joint architecture is still reasonably intact. There are clinical and imaging markers that reliably identify patients who are unlikely to benefit from joint preservation: joint space narrowing below two millimeters, advanced osteoarthritis on X-ray, cartilage damage on both the ball and socket sides, and mechanical symptoms like locking or catching.²³ When a hip reaches that stage, attempting biological repair may delay an inevitable joint replacement while subjecting the patient to procedures that have little chance of success.

For younger adults especially, there is a real tension between wanting to preserve the native joint and recognizing when the damage has crossed a threshold. A well-timed total hip replacement in a young patient with advanced cartilage loss often produces better functional outcomes and faster return to activity than pursuing multiple biological repair attempts that ultimately fail. Advances in MRI, including T2 mapping technology that can objectively measure cartilage quality across different zones of the hip, are making it easier to stage damage accurately and identify the patients most likely to benefit from repair versus replacement.²⁴

Biomarkers and the Push Toward Earlier Detection

One of the biggest frustrations in treating hip cartilage damage is that by the time symptoms drive someone to seek help, the damage is often advanced. X-rays only show cartilage loss indirectly, through narrowing of the gap between bones, and that narrowing becomes visible only after substantial tissue is already gone. This is why researchers are working on molecular biomarkers, measurable substances in blood, urine, or joint fluid, that could flag cartilage breakdown while it is still in its earliest stages. A systematic review found that such biomarkers have genuine potential to improve diagnosis, staging, and prognosis of hip osteoarthritis and pre-arthritic hip conditions.²⁵

The practical significance is this: if cartilage damage could be detected much earlier, many of the repair strategies that currently seem limited might become far more effective. Microfracture, stem cell injections, and growth factor therapies all perform better on smaller, earlier-stage defects. A future in which routine blood tests or advanced imaging catch hip cartilage problems before they become symptomatic would fundamentally change the calculus, moving cartilage treatment from a salvage operation to genuine early-stage repair. That future is not here yet, but the pieces are being assembled.